DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

NCT00302341 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped FDA Clinical Hold as of 12/21/07 due to safety concerns

Conditions

Pneumonia, Interstitial Plasma Cell
Pneumocystis Carinii Pneumonia
Pneumonia, Pneumocystis Carinii
HIV Infections

Interventions

DRUG: Pafuramidine maleate (DB289)
DRUG: Trimethoprim-Sulfamethoxazole (TMP-SMX)

Sponsor

Immtech Pharmaceuticals, Inc